212 related articles for article (PubMed ID: 34929991)
1. Cutaneous adverse effects of biologic drugs in psoriasis: a literature review.
Šuler Baglama Š; Trčko K
Acta Dermatovenerol Alp Pannonica Adriat; 2021 Dec; 30(4):149-156. PubMed ID: 34929991
[TBL] [Abstract][Full Text] [Related]
2. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.
Carrascosa JM; Del-Alcazar E
Expert Rev Clin Immunol; 2018 Apr; 14(4):259-273. PubMed ID: 29557200
[TBL] [Abstract][Full Text] [Related]
3. [Biologics. New drugs, new adverse reactions].
Prinz JC
Hautarzt; 2010 Aug; 61(8):668-75. PubMed ID: 20585746
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Manifestations of Reactions to Biologics.
Otani IM; Levin AS; Banerji A
Curr Allergy Asthma Rep; 2018 Feb; 18(2):12. PubMed ID: 29464437
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory/infectious cutaneous side effects of biological drugs in patients with psoriasis: a general review with personal data.
Rongioletti F; Burlando M; Parodi A
G Ital Dermatol Venereol; 2014 Jun; 149(3):311-6. PubMed ID: 24819758
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab for treating plaque psoriasis.
Rothstein B; Gottlieb A
Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
[TBL] [Abstract][Full Text] [Related]
7. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
[TBL] [Abstract][Full Text] [Related]
8. New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection.
Ceccarelli M; Venanzi Rullo E; Berretta M; Cacopardo B; Pellicanò GF; Nunnari G; Guarneri C
Dermatol Ther; 2021 Jan; 34(1):e14660. PubMed ID: 33301216
[TBL] [Abstract][Full Text] [Related]
9. Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis.
Henderson Berg MH; Carrasco D
J Drugs Dermatol; 2017 Jul; 16(7):695-698. PubMed ID: 28697222
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab for the Treatment of Psoriasis.
Machado Á; Torres T
BioDrugs; 2018 Apr; 32(2):119-128. PubMed ID: 29470778
[TBL] [Abstract][Full Text] [Related]
11. Adverse Reactions to Biologics in Psoriasis.
Lockwood SJ; Prens LM; Kimball AB
Curr Probl Dermatol; 2018; 53():1-14. PubMed ID: 29131033
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review.
Kamata M; Tada Y
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32121574
[TBL] [Abstract][Full Text] [Related]
13. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities.
Mateu-Arrom L; Puig L
Expert Rev Clin Pharmacol; 2024 Apr; 17(4):363-379. PubMed ID: 38603464
[TBL] [Abstract][Full Text] [Related]
14. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
D'Adamio S; Silvaggio D; Lombardo P; Bianchi L; Talamonti M; Galluzzo M
Expert Opin Drug Saf; 2019 Nov; 18(11):1031-1041. PubMed ID: 31479282
[No Abstract] [Full Text] [Related]
15. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.
Gaspari AA; Tyring S
Dermatol Ther; 2015; 28(4):179-93. PubMed ID: 26201310
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
17. Biologics in pediatric psoriasis.
Wang WM; Jin HZ
J Dermatol; 2023 Apr; 50(4):415-421. PubMed ID: 36651087
[TBL] [Abstract][Full Text] [Related]
18. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
19. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
Borren NZ; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
